Replies to post #27953 on Amarin Corp Plc (AMRN)

[James364202]

GS-If this information is verified, It would indicate that Epanova, a potential major competitor of Vascepa, has thrown in the towel. AZN may have figured that triple damages on patent infringement were too much to risk and AMRN's patents were too strong! Also, IMHO, AZN may have decided that pure EPA was the better product. Both Lovaza and Epanova contain EPA and DHA, just like fish oil does. I believe the DHA blocks some of the good effects of pure EPA, Reduce-It will tell the tale!